Pathstone Family Office’s Celgene Corp CELG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
Sell
-1,000
Closed -$99K 689
2019
Q3
$99K Sell
1,000
-100
-9% -$9.5K 0.01% 197
2019
Q2
$101K Sell
1,100
-450
-29% -$42.7K 0.01% 257
2019
Q1
$145K Buy
1,550
+1,450
+1,450% +$127K 0.02% 199
2018
Q4
$6K Hold
100
﹤0.01% 369
2018
Q3
$9K Buy
+100
New +$8.84K ﹤0.01% 165
2018
Q2
Sell
-119
Closed -$11K 379
2018
Q1
$11K Hold
119
0.01% 219
2017
Q4
$12K Sell
119
-116
-49% -$13.1K 0.01% 104
2017
Q3
$35K Buy
235
+81
+53% +$11K 0.03% 84
2017
Q2
$20K Sell
154
-130
-46% -$15.9K 0.01% 280
2017
Q1
$35K Buy
+284
New +$34K 0.02% 204
2016
Q4
Sell
-459
Closed -$47K 238
2016
Q3
$47K Buy
459
+274
+148% +$29.7K 0.05% 65
2016
Q2
$18K Buy
185
+135
+270% +$14K 0.02% 97
2016
Q1
$5K Buy
+50
New +$5.15K 0.01% 151
2015
Q4
Sell
-50
Closed -$5K 185
2015
Q3
$5K Buy
+50
New +$6.21K 0.01% 127
2014
Q4
Sell
-280
Closed -$27K 333
2014
Q3
$27K Buy
+280
New +$25.3K 0.08% 98

Other funds holding CELG

Pathstone Family Office's CELG Position: Q4 2019 in Review

Pathstone Family Office sold out of Celgene Corp (CELG) in Q4 2019, closing a stake of 1,000 shares — an estimated $99K sold.

Pathstone Family Office first reported a position in CELG in Q3 2014 and held it in 15 quarters. The position peaked at $145K in Q1 2019. 4 funds tracked by Wall St. Rank hold CELG as of Q4 2019.

  • Pathstone Family Office reported no remaining Celgene Corp position as of Q4 2019 after selling out during the quarter.
  • Pathstone Family Office sold 1,000 Celgene Corp shares in Q4 2019, an estimated $99K.
  • Pathstone Family Office first reported a position in Celgene Corp in Q3 2014 and held it in 15 quarters.
  • Pathstone Family Office's Celgene Corp position peaked at $145K in Q1 2019.
  • 4 funds tracked by Wall St. Rank held Celgene Corp as of Q4 2019.

Based on Pathstone Family Office's 13F filing for Q4 2019, filed 14 Feb 2020.